To provide a drug including a compound having an antagonistic activity with respect to EP4 receptor in preventing and/or treating the disease caused by activation of an EP4 receptor as an active ingredient. A compound represented by the general formula (I):
(wherein in the formula, all the symbols have the same meanings as those described in the description), or a pharmaceutically acceptable salt thereof is useful as a medicament component having an EP4 receptor antagonistic activity, in preventing and/or treating the disease caused by activation of an EP4 receptor.
A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
Combination comprising EP4 antagonist and immune checkpoint inhibitor
申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:US11065226B2
公开(公告)日:2021-07-20
A medicament comprising a combination of a compound represented by formula (I),
a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these and an immune checkpoint inhibitor (such as an anti-PD-1 antibody), which exhibits a strong anti-tumor effect and thus is useful for the treatment of cancer.